Eli Lilly SG&A Expenses 2010-2024 | LLY

Eli Lilly sg&a expenses for the twelve months ending September 30, 2024 were $8.094B, a 13.65% increase year-over-year.

  • Eli Lilly annual sg&a expenses for 2023 were $7.403B, a 14.95% increase from 2022.
  • Eli Lilly annual sg&a expenses for 2022 were $6.44B, a 0.14% increase from 2021.
  • Eli Lilly annual sg&a expenses for 2021 were $6.432B, a 5.07% increase from 2020.

Eli Lilly SG&A Expenses 2010-2024 | LLY

  • Eli Lilly annual sg&a expenses for 2023 were $7.403B, a 14.95% increase from 2022.
  • Eli Lilly annual sg&a expenses for 2022 were $6.44B, a 0.14% increase from 2021.
  • Eli Lilly annual sg&a expenses for 2021 were $6.432B, a 5.07% increase from 2020.
Related Stocks
Company NameMarket
Cap
Novo Nordisk (NVO)$460.6B
Johnson & Johnson (JNJ)$368.4B
AbbVie (ABBV)$294.4B
Merck (MRK)$244.2B
Novartis AG (NVS)$211.1B
AstraZeneca (AZN)$197.8B
Pfizer (PFE)$142.2B
Sanofi (SNY)$121.8B
Innoviva (INVA)$1.2B